ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN ASPIRIN DAN CLOPIDOGREL PADA PASIEN STROKE ISKEMIK RAWAT INAP DI RUMAH SAKIT ROYAL PRIMA TAHUN 2022–2025

Nursaima Putri  Nasution; Daimah Wirdatus Sanaun Harahap; Astriani Natalia  Br Ginting

doi:10.36805/jbf.v6i1.1647

Nursaima Putri Nasution Bachelor of Clinical Pharmacy, Faculty of Health Sciences, Universitas Prima Indonesia, Medan, 20118 , Indonesia
Daimah Wirdatus Sanaun Harahap Department of Clinical Pharmacy, Faculty of Health Sciences, Universitas Prima Indonesia, Medan, , 20118 , Indonesia
Astriani Natalia Br Ginting PUI Phyto Degenerative & Lifestyle Medicine, Universitas Prima Indonesia

DOI: https://doi.org/10.36805/jbf.v6i1.1647

Keywords: ischemic stroke, aspirin, clopidogrel, cost-effectiveness analysis, pharmacoeconomics

Abstract

Ischemic stroke is one of the leading causes of mortality and long-term disability, imposing a substantial economic burden due to high treatment and rehabilitation costs. Antiplatelet therapies such as aspirin and clopidogrel are commonly used for secondary prevention to reduce the risk of recurrent stroke; however, differences in treatment costs require evaluation to support efficient use of healthcare resources. This study aimed to analyze and compare the total cost and cost-effectiveness of aspirin and clopidogrel therapy in patients with ischemic stroke at Royal Prima General Hospital during the period 2022-2025. This study was an observational analytic study with a retrospective design using patients’ medical record data. The analysis was conducted from the hospital perspective by calculating direct medical costs, including drug costs, hospitalization, diagnostic examinations, and medical procedures. Pharmacoeconomic evaluation was performed using the Cost-Effectiveness Analysis (CEA) approach, with cost-effectiveness assessed through the calculation of the Cost-Effectiveness Ratio (CER) based on patients’ clinical outcomes. The results demonstrated differences in total treatment costs between aspirin and clopidogrel therapy, influenced by variations in cost components and patients’ clinical characteristics. In conclusion, cost-effectiveness analysis using CEA and CER can provide a scientific basis for selecting antiplatelet therapy that is rational and cost-efficient in the management of patients with ischemic stroke.

References

Doyeon Hwang, M. (2023) ‘Cost-Effectiveness of Clopidogrel vs Aspirin Monotherapy After Percutaneous Coronary Intervention’, 3(2). Available at: https://doi.org/10.1016/j.jacasi.2022.12.007.

Fitria, N. et al. (2024) ‘narra j Aspirin-clopidogrel combination therapy for ischemic stroke patients : Clinical efficacy and’, pp. 1–10.

Hidayat, R. et al. (2022) ‘Clopidogrel Resistance Among Ischemic Stroke Patients and Its Risk Factors in Indonesia’, 51(1), pp. 29–34. Available at: https://doi.org/10.5644/ama2006-124.367.

Kaban, P.L.R.A. et al. (2023) ‘ANALISIS BIAYA PERAWATAN PASIEN STROKE DI RUMAH SAKIT ROYAL PRIMA TAHUN 2020 Panta’, AT-TAWASSUTH: Jurnal Ekonomi Islam, VIII(I), pp. 1–19.

Kamarova, M. et al. (2022) ‘Antiplatelet Use in Ischemic Stroke’. Available at: https://doi.org/10.1177/10600280211073009.

Kleindorfer, D.O. et al. (2021) 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association, Stroke. Available at: https://doi.org/10.1161/STR.0000000000000375.

Lavanya, S. et al. (2024) ‘Clopidogrel Resistance in Ischemic Stroke Patients’, pp. 493–497. Available at: https://doi.org/10.4103/aian.aian.

Natalia, A. et al. (2025) ‘Formulasi dan Uji Aktivitas Antibakteri Gel Minyak Atsiri Rimpang Lengkuas Merah ( Alpinia purpurata K . Schum ) terhadap Propionibacterium acnes’, 4(1), pp. 75–88. Available at: https://doi.org/10.55123/insologi.v4i1.4844.

Nurkhalica, S. et al. (2025) ‘Analisis Efektivitas Biaya Penggunaan Terapi Aspirin Tunggal Dan Kombinasi Aspirin-Clopidogrel Pada Pasien Sindrom Koroner Akut Di Rsud Dr. Moewardi’, Jurnal Ilmiah Global Farmasi (JIGF), 3(1), pp. 10–20.

Prasad, K. et al. (2018) ‘Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: A clinical practice guideline’, The BMJ, 363. Available at: https://doi.org/10.1136/bmj.k5130.

Tonin, F.S. et al. (2021) ‘Principles of pharmacoeconomic analysis : the case of pharmacist-led interventions’, 19(1), pp. 1–10.

Venketasubramanian, N., Yudiarto, F.L. and Tugasworo, D. (2022) ‘Stroke Burden and Stroke Services in Indonesia’, Cerebrovascular Diseases Extra, 12(1), pp. 53–57. Available at: https://doi.org/10.1159/000524161.

Wirdatus, D. et al. (2024) ‘Medication Adherence among Drug-Resistant Tuberculosis ( DR-TB ) Patients at Universitas Indonesia Hospital’, 44(3).

World Health Organization (2020) ‘Avoiding Heart Attacks and Strokes Don’t be a victim - Protect Yourself’, WHO Library Cataloguing in publication Data, pp. 1–4.

Yosmar, R., Febiana, D. and Fitria, N. (2023) ‘Evaluating Economic Outcomes: Single-Use Aspirin vs. Aspirin-Clopidogrel in Ischemic Stroke Patients Based on Barthel Index Scores’, Jurnal Sains Farmasi & Klinis, 10(3), p. 293. Available at: https://doi.org/10.25077/jsfk.10.3.293-299.2023.

Zainuddin, A.A. et al. (2025) ‘The major risk factor of stroke across Indonesia; a nationwide geospatial analysis of universal health coverage program’, Archives of Public Health, 83(1). Available at: https://doi.org/10.1186/s13690-025-01613-4.